Skip to main content
Journal cover image

A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.

Publication ,  Journal Article
Wong, NS; Fernando, NH; Bendell, JC; Morse, MA; Blobe, GC; Honeycutt, W; Pang, H; Hurwitz, HI
Published in: Clin Colorectal Cancer
September 2011

BACKGROUND: This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer. PATIENTS AND METHODS: Nineteen patients with previously untreated advanced colorectal cancer received capecitabine at 1000 mg/m(2) twice a day on days 1-5 and days 8-12 of a 14-day cycle, and OHP at 85 mg/m(2) and bevacizumab at 10 mg/kg every 2 weeks. Because of unacceptable toxicities, the capecitabine dose was reduced to 850 mg/m(2). Thirty-one additional patients were treated at the lower capecitabine dose. Treatment continued until disease progression, persistent intolerable toxicity, or physician and/or patient discretion. RESULTS: Overall, toxicities were better managed and tolerated at the 850 mg/-m(2) capecitabine dose. The most common treatment-related grade ≥ 3 toxicities were diarrhea and sensory neuropathy. In the first 19 subjects, the response rate was 63% (95% confidence interval [CI], 38%-84%) and 5 patients had stable disease; median progression-free survival (PFS) was 10.1 months (95% CI, 5.7-19.5 months). In the subsequent 31 patients, the response was 42% (95% CI, 25%-61%); 11 patients had stable disease and median PFS was 10.4 months (95% CI, 6.9-15.4); median overall survival was 24.8 months (95% CI, 12.9-39.7). CONCLUSIONS: This novel regimen of capecitabine at 850 mg/m(2) twice a day on days 1-5 and days 8-12 and OHP at 85 mg/m(2)and bevacizumab at 10 mg/kg every 14 days is clinically active in advanced colorectal cancer. The toxicity profile of this regimen is consistent with the standard every-3-week dosing schedule.

Duke Scholars

Published In

Clin Colorectal Cancer

DOI

EISSN

1938-0674

Publication Date

September 2011

Volume

10

Issue

3

Start / End Page

210 / 216

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Survival Rate
  • Oxaliplatin
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wong, N. S., Fernando, N. H., Bendell, J. C., Morse, M. A., Blobe, G. C., Honeycutt, W., … Hurwitz, H. I. (2011). A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer, 10(3), 210–216. https://doi.org/10.1016/j.clcc.2011.03.018
Wong, Nan Soon, Nishan H. Fernando, Johanna C. Bendell, Michael A. Morse, Gerard C. Blobe, Wanda Honeycutt, Herbert Pang, and Herbert I. Hurwitz. “A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.Clin Colorectal Cancer 10, no. 3 (September 2011): 210–16. https://doi.org/10.1016/j.clcc.2011.03.018.
Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, et al. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2011 Sep;10(3):210–6.
Wong, Nan Soon, et al. “A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.Clin Colorectal Cancer, vol. 10, no. 3, Sept. 2011, pp. 210–16. Pubmed, doi:10.1016/j.clcc.2011.03.018.
Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2011 Sep;10(3):210–216.
Journal cover image

Published In

Clin Colorectal Cancer

DOI

EISSN

1938-0674

Publication Date

September 2011

Volume

10

Issue

3

Start / End Page

210 / 216

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Survival Rate
  • Oxaliplatin
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Follow-Up Studies